カテゴリー： 世界, 医療/バイオ, Transparency Market Research

世界のカテコールアミン市場2023-2031：薬剤別（内因性、合成）、疾患別（アナフィラキシー、心停止、急性喘息、ショック、低血圧、その他）

【英語タイトル】Catecholamines Market (Drug Type: Endogenous and Synthetic; Indication: Anaphylaxis, Cardiac Arrest, Acute Asthma, Shock, Hypotension, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが出版した調査資料（TMR23JUL043）・商品コード：TMR23JUL043
・発行会社（調査会社）：Transparency Market Research
・発行日：2023年5月
・ページ数：196
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Transparency Market Research社の当調査資料では、世界のカテコールアミン市場規模が、2023年の40億ドルから2031年までに67億ドルに成長し、予測期間中に年平均5.9%で拡大すると予想しています。本書は、カテコールアミンの世界市場について調べ、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（内因性、合成）分析、投与経路別（静脈、吸入、経皮、その他）分析、疾患別（アナフィラキシー、心停止、急性喘息、ショック、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目をまとめています。なお、当市場の主要企業として、Pfizer, Inc.,、Baxter International、Novartis International AG (Sandoz)、Breckenridge Pharmaceutical, Inc.、Viatris, Inc. (Mylan N.V)、Mallinckrodt Pharmaceuticals、Amneal Pharmaceuticals、Lexicare Pharma Pvt. Ltd.、Midas Pharma GmbH、Armstrong Pharmaceuticals, Inc.、Adamis Pharmaceuticals Corporation、Teva Pharmaceutical Industries Ltd.などが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のカテコールアミン市場規模：薬剤別
- 内因性カテコールアミンの市場規模
- 合成カテコールアミンの市場規模
・世界のカテコールアミン市場規模：投与経路別
- 静脈投与における市場規模
- 吸入投与における市場規模
- 経皮投与における市場規模
- その他投与経路における市場規模
・世界のカテコールアミン市場規模：疾患別
- アナフィラキシーにおける市場規模
- 心停止における市場規模
- 急性喘息における市場規模
- ショックにおける市場規模
- その他疾患における市場規模
・世界のカテコールアミン市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のカテコールアミン市場規模：地域別
- 北米のカテコールアミン市場規模
- ヨーロッパのカテコールアミン市場規模
- アジア太平洋のカテコールアミン市場規模
- 中南米のカテコールアミン市場規模
- 中東・アフリカのカテコールアミン市場規模
・競争状況

Catecholamines Market – Scope of Report
TMR’s report on the global Catecholamines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Catecholamines market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Catecholamines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Catecholamines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Catecholamines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Catecholamines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Catecholamines market.

The report delves into the competitive landscape of the global Catecholamines market. Key players operating in the global Catecholamines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Catecholamines market profiled in this report.

Key Questions Answered in Global Catecholamines Market Report
• What is the sales/revenue generated by Catecholamines across all regions during the forecast period?
• What are the opportunities in the global Catecholamines market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Catecholamines Market – Research Objectives and Research Approach
The comprehensive report on the global Catecholamines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Catecholamines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Catecholamines market.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Catecholamines Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Catecholamines Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Overview of Catecholamines Market
    5.2. Regulatory Scenario Globally/Region
    5.3. Pipeline Analysis
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Catecholamines Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2017-2031
        6.3.1. Endogenous
        6.3.2. Synthetic
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Catecholamines Market Analysis and Forecast, by Route of Administration
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Route of Administration, 2017-2031
        7.3.1. Intravenous
        7.3.2. Inhalation
        7.3.3. Transdermal
        7.3.4. Others
    7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Catecholamines Market Analysis and Forecasts, by Indication
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2017-2031
        8.3.1. Anaphylaxis
        8.3.2. Cardiac Arrest
        8.3.3. Acute Asthma
        8.3.4. Shock
        8.3.5. Hypertension
        8.3.6. Others
    8.4. Market Attractiveness Analysis, by Indication
9. Global Catecholamines Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017-2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Catecholamines Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, By Region
11. North America Catecholamines Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017-2031
        11.2.1. Endogenous
        11.2.2. Synthetic
    11.3. Market Value Forecast, by Route of Administration, 2017-2031
        11.3.1. Intravenous
        11.3.2. Inhalation
        11.3.3. Transdermal
        11.3.4. Others
    11.4. Market Value Forecast, by Indication, 2017-2031
        11.4.1. Anaphylaxis
        11.4.2. Cardiac Arrest
        11.4.3. Acute Asthma
        11.4.4. Shock
        11.4.5. Hypertension
        11.4.6. Others
    11.5. Market Value Forecast, by Distribution Channel, 2017-2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Type
        11.7.2. By Route of Administration
        11.7.3. By Indication
        11.7.4. By Distribution Channel
        11.7.5. By Country
12. Europe Catecholamines Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017-2031
        12.2.1. Endogenous
        12.2.2. Synthetic
    12.3. Market Value Forecast, by Route of Administration, 2017-2031
        12.3.1. Intravenous
        12.3.2. Inhalation
        12.3.3. Transdermal
        12.3.4. Others
    12.4. Market Value Forecast, by Indication, 2017-2031
        12.4.1. Anaphylaxis
        12.4.2. Cardiac Arrest
        12.4.3. Acute Asthma
        12.4.4. Shock
        12.4.5. Hypertension
        12.4.6. Others
    12.5. Market Value Forecast, by Distribution Channel, 2017-2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Type
        12.7.2. By Route of Administration
        12.7.3. By Indication
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region
13. Asia Pacific Catecholamines Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017-2031
        13.2.1. Endogenous
        13.2.2. Synthetic
    13.3. Market Value Forecast, by Route of Administration, 2017-2031
        13.3.1. Intravenous
        13.3.2. Inhalation
        13.3.3. Transdermal
        13.3.4. Others
    13.4. Market Value Forecast, by Indication, 2017-2031
        13.4.1. Anaphylaxis
        13.4.2. Cardiac Arrest
        13.4.3. Acute Asthma
        13.4.4. Shock
        13.4.5. Hypertension
        13.4.6. Others
    13.5. Market Value Forecast, by Distribution Channel, 2017-2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Type
        13.7.2. By Route of Administration
        13.7.3. By Indication
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region
14. Latin America Catecholamines Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017-2031
        14.2.1. Endogenous
        14.2.2. Synthetic
    14.3. Market Value Forecast, by Route of Administration, 2017-2031
        14.3.1. Intravenous
        14.3.2. Inhalation
        14.3.3. Transdermal
        14.3.4. Others
    14.4. Market Value Forecast, by Indication, 2017-2031
        14.4.1. Anaphylaxis
        14.4.2. Cardiac Arrest
        14.4.3. Acute Asthma
        14.4.4. Shock
        14.4.5. Hypertension
        14.4.6. Others
    14.5. Market Value Forecast, by Distribution Channel, 2017-2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Type
        14.7.2. By Route of Administration
        14.7.3. By Indication
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region
15. Middle East & Africa Catecholamines Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Type, 2017-2031
        15.2.1. Endogenous
        15.2.2. Synthetic
    15.3. Market Value Forecast, by Route of Administration, 2017-2031
        15.3.1. Intravenous
        15.3.2. Inhalation
        15.3.3. Transdermal
        15.3.4. Others
    15.4. Market Value Forecast, by Indication, 2017-2031
        15.4.1. Anaphylaxis
        15.4.2. Cardiac Arrest
        15.4.3. Acute Asthma
        15.4.4. Shock
        15.4.5. Hypertension
        15.4.6. Others
    15.5. Market Value Forecast, by Distribution Channel, 2017-2031
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Type
        15.7.2. By Route of Administration
        15.7.3. By Indication
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Pfizer, Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Baxter International
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Novartis International AG (Sandoz)
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Breckenridge Pharmaceutical, Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Viatris, Inc. (Mylan N.V)
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Mallinckrodt Pharmaceuticals
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Amneal Pharmaceuticals.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Lexicare Pharma Pvt. Ltd.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Midas Pharma GmbH
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Armstrong Pharmaceuticals, Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Adamis Pharmaceuticals Corporation
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Teva Pharmaceutical Industries Ltd.
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview

List of Tables

Table 01: Global Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 02: Global Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 03: Global Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 04: Global Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 05: Global Catecholamines Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06: North America Catecholamines Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 07: North America Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 08: North America Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 09: North America Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 10: North America Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 11: Europe Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 12: Europe Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 13: Europe Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 14: Europe Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 15: Europe Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 16: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 18: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 19: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 20: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 21: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 23: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 24: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 25: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 26: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 28: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 29: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 30: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

★調査レポート[世界のカテコールアミン市場2023-2031：薬剤別（内因性、合成）、疾患別（アナフィラキシー、心停止、急性喘息、ショック、低血圧、その他）] (コード：TMR23JUL043)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のカテコールアミン市場2023-2031：薬剤別（内因性、合成）、疾患別（アナフィラキシー、心停止、急性喘息、ショック、低血圧、その他）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の自動注射器市場2023-2031：種類別（使い捨て、再利用可能）、技術別（ハンドヘルド型、ウェアラブル型）、疾患別（多発性硬化症、関節リウマチ、糖尿病、アナフィラキシー、その他）
  • 世界の自動注射器市場（～2030年）：種類別（使い捨て、再利用可能）、投与経路別（皮下、筋肉内）、治療法別（アナフィラキシー、喘息、糖尿病、その他）、分子種類別、流通チャネル別、エンドユーザー別、地域別
  • 世界のプレフィルドオートインジェクター（薬剤充填済み自動注射器）市場2023-2033：疾患別（アナフィラキシー、多発性硬化症、関節リウマチ）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、ドラッグストア）、地域別
  • 自動注射器のグローバル市場（2023～2028）：関節リウマチ、多発性硬化症、アナフィラキシー、その他
  • 世界の新型コロナウイルス感染症治療薬市場（2022-2031）：薬剤クラス別（コルチコステロイド、抗ウイルス剤、モノクローナル抗体、キナーゼ阻害剤、その他（抗炎症剤、回復期血漿、その他））
  • 世界の融合阻害剤市場2022-2031：疾患別（HIV/AIDS、新型コロナウイルス感染症）、投与経路別（非経口、経口）
  • 世界の急性片頭痛治療薬市場2022-2031：薬剤種類別（トリプタン系薬剤、CGRP拮抗剤、非ステロイド性抗炎症薬、β-アドレナリン遮断薬、エルゴアルカロイド系薬剤、その他）
  • 世界のカルシウムチャネル遮断薬市場2023-2031：薬剤クラス別（フェニルアルキルアミン、ベンゾチゼピン、ジヒドロピリジン）、用途別（高血圧、扁桃炎、不整脈、肥大型心筋症、その他）、投与経路別（経口、非経口）

    • ◆H&Iグローバルリサーチのお客様（例）◆